Breaking News, Collaborations & Alliances

Anthos, Lonza Partnership to Address Thrombotic Disorders

Development and manufacturing deal leverages Lonza’s network of process development and GMP-manufacturing facilities across Europe and the US for Abelacimab

By: Contract Pharma

Contract Pharma Staff

Lonza has entered a partnership agreement with Anthos Therapeutics, a biotech created by Blackstone Life Sciences and Novartis. The partnership supports the development and manufacturing of Abelacimab, a novel, fully human, Factor XI and XIa antibody, which could, if approved, address a range of thrombotic disorders.   Lonza will leverage its integrated end-to-end offering, developed specifically for virtual biotechs and their investors. The company says its milestone business model is designed ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters